No connection

Search Results

ANIK vs TNXP

ANIK
Anika Therapeutics, Inc.
BEARISH
Price
$14.20
Market Cap
$204.8M
Sector
Healthcare
AI Confidence
85%
TNXP
Tonix Pharmaceuticals Holding Corp.
BEARISH
Price
$14.34
Market Cap
$203.7M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
ANIK
--
TNXP
--
Forward P/E
ANIK
35.5
TNXP
-2.78
P/B Ratio
ANIK
1.37
TNXP
0.75
P/S Ratio
ANIK
1.82
TNXP
15.54
EV/EBITDA
ANIK
-29.07
TNXP
0.11

Profitability

Gross Margin
ANIK
56.56%
TNXP
49.34%
Operating Margin
ANIK
2.11%
TNXP
-895.84%
Profit Margin
ANIK
-9.64%
TNXP
0.0%
ROE
ANIK
-6.71%
TNXP
-64.48%
ROA
ANIK
-3.52%
TNXP
-35.71%

Growth

Revenue Growth
ANIK
0.0%
TNXP
108.8%
Earnings Growth
ANIK
--
TNXP
--

Financial Health

Debt/Equity
ANIK
0.18
TNXP
0.01
Current Ratio
ANIK
4.72
TNXP
7.42
Quick Ratio
ANIK
3.71
TNXP
6.96

Dividends

Dividend Yield
ANIK
--
TNXP
--
Payout Ratio
ANIK
0.0%
TNXP
0.0%

AI Verdict

ANIK BEARISH

ANIK's Piotroski F-Score of 2/9 indicates weak financial health, with significant red flags in profitability and cash flow. The company reports negative net income and ROE, despite a strong gross margin of 56.56%, suggesting operational inefficiencies. While the debt-to-equity ratio of 0.18 and high current ratio (4.72) point to solid liquidity, the lack of revenue growth (0% YoY) and absence of free cash flow undermine long-term sustainability. The stock trades at a forward P/E of 35.50, which is elevated relative to its lack of earnings growth, and the 63.8% 6-month rally appears speculative rather than fundamentals-driven. Analysts rate it 'strong_buy' with a target of $17.50, but this is not supported by core financial metrics.

Strengths
High gross margin (56.56%) indicates strong pricing power and cost control in production
Strong liquidity position with current ratio of 4.72 and quick ratio of 3.71
Low debt-to-equity ratio (0.18) suggests conservative capital structure
Risks
Piotroski F-Score of 2/9 signals poor financial health and high distress risk
Negative net profit margin (-9.64%) and ROE (-6.71%) indicate unprofitable operations
Zero revenue growth (0% YoY) despite a growing market cap, suggesting stagnation
TNXP BEARISH

TNXP exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a catastrophic operating margin of -895.84%. While the company maintains a high current ratio (7.42) and low debt, these are likely the result of aggressive equity dilution rather than operational success, as evidenced by a -100% 5-year price return. Despite a 'strong_buy' analyst consensus and high revenue growth, the lack of earnings beats (0/4 in the last year) and a total collapse in long-term shareholder value indicate a high-risk profile. The disconnect between the analyst target price ($54.33) and the fundamental decay is extreme.

Strengths
Strong YoY revenue growth of 108.80%
High liquidity with a current ratio of 7.42
Very low debt-to-equity ratio (0.01)
Risks
Extreme operational inefficiency (Operating Margin -895.84%)
Critical financial health (Piotroski F-Score 1/9)
Consistent failure to meet earnings estimates (0/4 last 4 quarters)

Compare Another Pair

ANIK vs TNXP: Head-to-Head Comparison

This page compares Anika Therapeutics, Inc. (ANIK) and Tonix Pharmaceuticals Holding Corp. (TNXP) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile